Abstract
Macular edema (ME) is a common, final pathway for many different ocular and systemic diseases. The most common diseases include: diabetic retinopathy (DR), retinal vascular disorders (such as central and branch retinal vein occlusion), and uveitis. The complex and multifactorial pathophysiological mechanisms leading to ME, are still poorly understood. Inflammation plays a crucial role in the genesis of ME, as demontrsated by significant increase of different cytokines and chemokines, (besides vascular endothelial growth factors-VEGF) in ocular fluids. Currently, intravitreal steroids and anti-VEGF drugs are the most used treatments in ME of retinal vascular origin. This review will address the most important (with highest level of scientific evidence and longest followup) results on the use of intravitreal steroids and anti-VEGF drugs, starting from molecular basis to the most updated randomized clinical trials.
Keywords: Macular edema, diabetes mellitus, retinal vein occlusion, uveitis, steroids, anti-VEGF.
Current Pharmaceutical Design
Title:Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Volume: 21 Issue: 32
Author(s): Stela Vujosevic and Edoardo Midena
Affiliation:
Keywords: Macular edema, diabetes mellitus, retinal vein occlusion, uveitis, steroids, anti-VEGF.
Abstract: Macular edema (ME) is a common, final pathway for many different ocular and systemic diseases. The most common diseases include: diabetic retinopathy (DR), retinal vascular disorders (such as central and branch retinal vein occlusion), and uveitis. The complex and multifactorial pathophysiological mechanisms leading to ME, are still poorly understood. Inflammation plays a crucial role in the genesis of ME, as demontrsated by significant increase of different cytokines and chemokines, (besides vascular endothelial growth factors-VEGF) in ocular fluids. Currently, intravitreal steroids and anti-VEGF drugs are the most used treatments in ME of retinal vascular origin. This review will address the most important (with highest level of scientific evidence and longest followup) results on the use of intravitreal steroids and anti-VEGF drugs, starting from molecular basis to the most updated randomized clinical trials.
Export Options
About this article
Cite this article as:
Vujosevic Stela and Midena Edoardo, Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909095645
DOI https://dx.doi.org/10.2174/1381612821666150909095645 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia The Structural Alteration and Aggregation of Bovine Lens Gamma-Crystallin by Homocysteinylation; The Pathomechanism Underlying Cataract Development During Hyperhomocysteinimia
Protein & Peptide Letters Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging The Genetics of Small-Vessel Disease
Current Medicinal Chemistry The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets
Current Pharmaceutical Design Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Compromise and Care of the Brains Compartments: The Quintessence of the Neurovascular Unit
Current Neurovascular Research Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Nucleoside Transporter Proteins
Current Vascular Pharmacology